A Study of LY3209590 in Participants With Type 2 Diabetes

What Was Tested

This registered phase 1 trial tested Insulin Glargine.

This study will evaluate the safety and tolerability of LY3209590 when given by injection under the skin to participants with type 2 diabetes.

It will also investigate how the body processes the study drug and the effect of the study drug on blood sugar levels.

Information about any side effects will be documented.

It had two arms (groups): LY3209590 (experimental) and Insulin glargine (active comparator).

Insulin glargine administered by SC injection.

The registry classes the interventions as drug.

Who Took Part

70 actual participants took part.

It was open to people of any sex aged from 18 years up to 70 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Participants with Type 2 Diabetes Mellitus (T2DM) for at least 1 year. Have had no episodes of severe hypoglycemia in the past 6 months.

The full record lists 4 inclusion and 8 exclusion criteria; among the exclusions: have a history of renal impairment; have a history of deep vein thrombosis of the leg or repeated episodes of deep leg vein thrombosis in first-degree relatives (parents, siblings, or children); have proliferative retinopathy or maculopathy and/or severe neuropathy.

How the Study Was Run

It was run as a randomized, parallel-group and open-label study.

Random assignment meant chance, not the researchers, decided who got Insulin Glargine and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Insulin Glargine was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2018-01-03 with completion listed for 2018-10-03.

It ran at 3 sites in United States (2) and Canada (1).

Its stated primary purpose is basic science.

What Was Measured

Researchers chose this as the main measure: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration (time frame: Baseline through 17 weeks).

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Insulin Glargine in 70 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Insulin Glargine compound page, all human trials.